Effects of long-term administration of enalapril on clinical indicators of renal function in dogs with compensated mitral regurgitation.

  title={Effects of long-term administration of enalapril on clinical indicators of renal function in dogs with compensated mitral regurgitation.},
  author={Clarke E Atkins and William A. Brown and Julie R Coats and Mary Ann Crawford and Teresa C DeFrancesco and Joel Edwards and Philip R Fox and Bruce W Keene and Linda B. Lehmkuhl and M.W. Luethy and Kathryn M. Meurs and J Petrie and Frank S. Pipers and Steven L. Rosenthal and Jennifer A Sidley and J Straus},
  journal={Journal of the American Veterinary Medical Association},
  volume={221 5},
OBJECTIVE To determine the effect of long-term administration of enalapril on renal function in dogs with severe, compensated mitral regurgitation. DESIGN Randomized controlled trial. ANIMALS 139 dogs with mitral regurgitation but without overt signs of heart failure. PROCEDURE Dogs were randomly assigned to be treated with enalapril (0.5 mg/kg [0.23 mg/lb], PO, q 24 h) or placebo, and serum creatinine and urea nitrogen concentrations were measured at regular intervals for up to 26 months… 

Figures from this paper

Long-term tolerability of benazepril in dogs with congestive heart failure.

  • J. PouchelonJ. King G. Strehlau
  • Medicine, Biology
    Journal of veterinary cardiology : the official journal of the European Society of Veterinary Cardiology
  • 2004

Results of the veterinary enalapril trial to prove reduction in onset of heart failure in dogs chronically treated with enalapril alone for compensated, naturally occurring mitral valve insufficiency.

Chronic enalapril treatment of dogs with naturally occurring, moderate to severe MR significantly delayed onset of CHF, compared with placebo, on the basis of number ofCHF-free days, number of dogs free of CHFs at days 500 and study end, and increased time to a combined secondary endpoint of CHf-all-cause death.

Safety of spironolactone in dogs with chronic heart failure because of degenerative valvular disease: a population-based, longitudinal study.

Dogs with heart failure receiving spironolactone in addition to conventional treatment are not at a higher risk for AEs, death caused by cardiac disease, renal disease, or both, hyperkalemia, or azotemia.

Effects of enalapril in cats with pressure overload-induced left ventricular hypertrophy

Effect of benazepril on survival and cardiac events in dogs with asymptomatic mitral valve disease: a retrospective study of 141 cases.

BNZ had beneficial effects in asymptomatic dogs other than C KC and KC affected by MVD with moderate-to-severe MR, and no effect of the BNZ treatment was observed in the CKC and KC population.

Prospective evaluation of renal function in dogs with chronic mitral valve disease

Looking at the prevalence of azotemia in CMVD dogs, data suggests a link between heart and kidney function (despite the authors didn’t excluded aged-related coexistence of organ damage) and no statistical evidence to support a difference in WRF parameters in dogs experiencing CHF and dogs not experiencing it is suggested.

Effect of tepoxalin on renal function in healthy dogs receiving an angiotensin-converting enzyme inhibitor.

It was concluded that tepoxalin did not alter renal function in healthy Beagle dogs receiving ACEI, and renal uptake and plasma clearance of 99mTc-DTPA were not significantly modified.

Losartan versus enalapril in dogs asymptomatic carriers of myxomatous degeneration of mitral valve

It is concluded that losartan acts similarly to enalapril in the initial treatment (first 56 days) of dogs with DMVM class Ib and II of the CHF.

Effect of standard-dose and high-dose pimobendan on select indices of renal and cardiac function in dogs with American College of Veterinary Internal Medicine stage B2 myxomatous mitral valve disease.

It is suggested that pimobendan (SD_pimo or HD-pimo) might not affect renal function in nonazotemic dogs with stage B2 MMVD and high-dose pimOBendan did not demonstrate advantages over SD_ pimo within the constraints of the authors' study.

Azotemia and glomerular filtration rate in dogs with chronic valvular disease.

Azotemia and renal impairment increase with the severity of congestive heart failure and are frequent findings in dogs with CVD and it remains to be shown if deterioration of renal function is a direct result of progression of the heart disease.



Functional renal insufficiency during long-term therapy with captopril and enalapril in severe chronic heart failure.

The deterioration of renal function after converting-enzyme inhibition in heart failure is not a toxic or immunologic reaction to therapy but results from specific hemodynamic events that can be ameliorated by sodium repletion.

Effects of enalapril maleate on survival of dogs with naturally acquired heart failure. The Long-Term Investigation of Veterinary Enalapril (LIVE) Study Group.

Use of enalapril in combination withstandard treatment (diuretics with or without digoxin) appears to be beneficial over an extended period, compared with standard treatment alone.

Acute and short-term hemodynamic, echocardiographic, and clinical effects of enalapril maleate in dogs with naturally acquired heart failure: results of the Invasive Multicenter PROspective Veterinary Evaluation of Enalapril study. The IMPROVE Study Group.

  • D. Sisson
  • Medicine
    Journal of veterinary internal medicine
  • 1995
This study shows the beneficial hemodynamic and clinical effects of adding enalapril to conventional therapy for dogs with heart failure and significantly greater decreases in class of heart failure, pulmonary edema score, and mobility score relative to baseline.

Controlled clinical evaluation of enalapril in dogs with heart failure: results of the Cooperative Veterinary Enalapril Study Group. The COVE Study Group.

  • J. Woodfield
  • Medicine
    Journal of veterinary internal medicine
  • 1995
The clinical efficacy and safety of enalapril were evaluated in dogs with moderate or severe heart failure and five dogs had to be removed from the study as a result of azotemia.

Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions.

The angiotensin-converting--enzyme inhibitor enalapril significantly reduced the incidence of heart failure and the rate of related hospitalizations, as compared with the rates in the group given placebo, among patients with asymptomatic left ventricular dysfunction.

Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).

  • Medicine
    The New England journal of medicine
  • 1987
It is concluded that the addition of enalapril to conventional therapy in patients with severe congestive heart failure can reduce mortality and improve symptoms and a significant improvement in NYHA classification was observed in the enAlapril group.

The effect of combined therapy with captopril, furosemide, and a sodium-restricted diet on serum electrolyte concentrations and renal function in normal dogs and dogs with congestive heart failure.

Six of 10 dogs with congestive heart failure had at least one serum potassium concentration above the reference range sometime during the 5 weeks of observation, although the changes in the mean serum potassium concentrations were not statistically significant.

A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure.

The different effects of the two regimens (enalapril and hydralazine-isosorbide dinitrate) on mortality and physiologic end points suggest that the profile of effects might be enhanced if the regimens were used in combination.